Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

References

• Horton ES. Defining the role of basal and prandial insulin for optimal glycemic control. J Am Coll Cardiol. 2009;53(5):S21–S27.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(1):S90–S102.
   PubMed Web of Science ®Google Scholar
• Khunti K, Caputo S, Damci T, et al. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes Obes Metab. 2012;14(12):1129–1136.
   PubMed Web of Science ®Google Scholar
• Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 Units mL−1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units mL−1. Diabetes Care. 2015;38(4):637–643.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus insulin glargine 100 U/mL in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab. 2015;17(12):1142–1149.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–2762.
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014;37(12):3235–3243.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386–394.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 Units/mL versus insulin degludec 100 Units/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care 2018;41(10):2147–2154.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Bailey TS, Roussel R, et al. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D + cohort study. Diabetes Obes Metab. 2018;20(9):2148–2158.
   PubMed Web of Science ®Google Scholar
• Zhou FL, Ye F, Berhanu P, et al. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. Diabetes Obes Metab. 2018;20(5):1293–1297.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20(3):488–496.
   PubMed Web of Science ®Google Scholar
• Garber AJ. The importance of titrating starting insulin regimens in patients with type 2 diabetes. Diabetes Obes Metab. 2009;11(5):10–13.
   PubMedGoogle Scholar
• Mauricio D, Meneghini L, Seufert J, et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017;19(8):1155–1164.
   PubMed Web of Science ®Google Scholar
• Ahren B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013;9:155–163.
   PubMedGoogle Scholar
• Brod M, Rana A, Barnett AH. Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses. Curr Med Res Opin. 2012;28(12):1933–1946.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682–689.
   PubMed Web of Science ®Google Scholar
• Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20(8):637–648.
   PubMedGoogle Scholar
• Goldman JD, Gill J, Horn T, et al. Improved treatment engagement among patients with diabetes treated with insulin glargine 300 U/mL who participated in the COACH support program. Diabetes Ther. 2018;9(5):2143–2153.
   PubMed Web of Science ®Google Scholar
• Zhou FL, Yeaw J, Karkare SU, et al. Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes. BMJ Open Diabetes Res Care. 2018;6(1):e000593.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2016. Diabetes Care 2016;39(1):S1–S112.
   PubMedGoogle Scholar
• Sanofi. Toujeo: Summary of product characteristics [Internet]. Paris (France): Sanofi; 2019 [cited 2019 Jan 23]. Available from: https://www.ema.europa.eu/documents/product-information/toujeo-epar-product-information_en.pdf.
   Google Scholar
• Standards of medical care in diabetes-2017: summary of revisions. Diabetes Care 2017;40(1):S4–S5.
   PubMedGoogle Scholar
• EMA. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [Internet]. Amsterdam (The Netherlands): European medicines Agency; 2012. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus-revision_en.pdf
   Google Scholar
• Oster G, Sullivan SD, Dalal MR, et al. Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naive patients with type 2 diabetes. Postgrad Med. 2016;128(8):731–739.
   PubMed Web of Science ®Google Scholar
• Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes. Diabetes Obes Metab. 2015;17(9):859–867.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Riddle MC, Bergenstal RM, et al. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naive people with type 2 diabetes: 12-month results from the EDITION 3 trial. Diabetes Metab. 2017;43(4):351–358.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Dauchy A, Delgado E, et al. Take control: a randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019;21(7):1615–1624.
   PubMed Web of Science ®Google Scholar